Annals of Hematology

, Volume 98, Issue 5, pp 1301–1303 | Cite as

Successful treatment of monomorphic epitheliotropic intestinal T cell lymphoma with pralatrexate

  • Rie TabataEmail author
  • Chiharu Tabata
  • Masahiko Okamura
  • Yusuke Takei
  • Koichi Ohshima
Letter to the Editor

Dear Editor,

A 72-year-old male was admitted to our hospital because of ileum perforation, and emergency surgery was performed. He was diagnosed with type II enteropathy-associated T cell lymphoma (EATL; Fig.  1a–f); he underwent chemotherapy and achieved complete remission (CR). However, the lymphoma recurred with bowel obstruction after 21 months. Operative resection of the intestinal tumor and chemotherapy were performed, following which second CR was achieved.


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189CrossRefGoogle Scholar
  2. 2.
    Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer/T-cell lymphoma study pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130CrossRefGoogle Scholar
  3. 3.
    Ferreri AJ, Zinzani PL, Govi S, Pileri SA (2011) Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol 79(1):84–90CrossRefGoogle Scholar
  4. 4.
    Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, Connors JM, Rimsza L, Harris NL, Müller-Hermelink K, Rüdiger T, Coiffier B, Gascoyne RD, Berger F, Tobinai K, Au WY, Liang R, Montserrat E, Hochberg EP, Pileri S, Federico M, Nathwani B, Armitage JO, Weisenburger DD (2011) Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 118(1):148–155CrossRefGoogle Scholar
  5. 5.
    Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, Ng SB, Chng WJ, Gatter K, Loong F, Liu YH, Hosking P, Cheah PL, Teh BT, Tay K, Koh M, Lim ST (2013) Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia 27(8):1688–1696CrossRefGoogle Scholar
  6. 6.
    Kikuma K, Yamada K, Nakamura S, Ogami A, Nimura S, Hirahashi M, Yonemasu H, Urabe S, Naito S, Matsuki Y, Sadahira Y, Takeshita M (2014) Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol 45(6):1276–1284CrossRefGoogle Scholar
  7. 7.
    Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS (2011) Multicenter retrospective analysis of 581 patients with primary intestinal non-Hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer 11:321CrossRefGoogle Scholar
  8. 8.
    Municio C, Dominguez-Soto Á, Fuentelsaz-Romero S, Lamana A, Montes N, Cuevas VD, Campos RG, Pablos JL, González-Álvaro I, Puig-Kröger A (2018) Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism. Ann Rheum Dis 77(5):752–759CrossRefGoogle Scholar
  9. 9.
    Kremer JM, Lawrence DA, Hamilton R, McInnes IB (2016) Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis. RMD Open 2(1):e000287CrossRefGoogle Scholar
  10. 10.
    Jaffe ES, Barr PM, Smith SM (2017) Understanding the New WHO Classification of Lymphoid Malignancies: why it’s important and how it will affect practice. Am Soc Clin Oncol Educ Book 37:535–546CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Rie Tabata
    • 1
    Email author
  • Chiharu Tabata
    • 2
  • Masahiko Okamura
    • 3
  • Yusuke Takei
    • 4
  • Koichi Ohshima
    • 5
  1. 1.Department of Hematology and RheumatologySaiseikai-Noe HospitalOsakaJapan
  2. 2.Cancer CenterHyogo College of MedicineNishinomiyaJapan
  3. 3.Department of SurgerySaiseikai Noe HospitalOsakaJapan
  4. 4.Department of PathologySaiseikai Noe HospitalOsakaJapan
  5. 5.Department of PathologySchool of Medicine, Kurume UniversityKurumeJapan

Personalised recommendations